BACKGROUND: Statins show anticancer activity in melanoma cells. We investigated the association between statins and incidence and Breslow thickness of cutaneous melanoma (CM). METHODS: Data were used from PHARMO, a pharmacy database, and PALGA, a pathological database, in the Netherlands. Cases had a primary CM diagnosis between January 1st 1991 and December 14th 2004, were 18 years and had 3 years of follow up in PHARMO before CM diagnosis. Controls were matched for gender, date of birth and geographic region. Analyses were adjusted for age, gender, year of diagnosis, number of medical diagnoses and the use of NSAIDs and oestrogens. FINDINGS: Finally, 1318 cases and 6786 controls were selected. CM risk was not associated with statin use (> or = 0.5 years) (adjusted odds ratio (OR)=0.98, 95% confidence interval (CI)=0.78-1.2). However, statin use was associated with a reduced Breslow thickness (-19%, 95% CI=-33, -2.3, p=0.03). CONCLUSION: Our study suggests protective effects of statins on melanoma progression.
BACKGROUND: Statins show anticancer activity in melanoma cells. We investigated the association between statins and incidence and Breslow thickness of cutaneous melanoma (CM). METHODS: Data were used from PHARMO, a pharmacy database, and PALGA, a pathological database, in the Netherlands. Cases had a primary CM diagnosis between January 1st 1991 and December 14th 2004, were 18 years and had 3 years of follow up in PHARMO before CM diagnosis. Controls were matched for gender, date of birth and geographic region. Analyses were adjusted for age, gender, year of diagnosis, number of medical diagnoses and the use of NSAIDs and oestrogens. FINDINGS: Finally, 1318 cases and 6786 controls were selected. CM risk was not associated with statin use (> or = 0.5 years) (adjusted odds ratio (OR)=0.98, 95% confidence interval (CI)=0.78-1.2). However, statin use was associated with a reduced Breslow thickness (-19%, 95% CI=-33, -2.3, p=0.03). CONCLUSION: Our study suggests protective effects of statins on melanoma progression.
Authors: Kenneth G Linden; Sancy A Leachman; Jonathan S Zager; James G Jakowatz; Jaye L Viner; Christine E McLaren; Ronald J Barr; Philip M Carpenter; Wen-Pin Chen; Craig A Elmets; Joseph A Tangrea; Sung-Jig Lim; Alistair J Cochran; Frank L Meyskens Journal: Cancer Prev Res (Phila) Date: 2014-03-10
Authors: Satu J Siiskonen; Els R Koomen; Loes E Visser; Ron M C Herings; Henk-Jan Guchelaar; Bruno H Ch Stricker; Tamar E C Nijsten Journal: Eur J Clin Pharmacol Date: 2013-03-08 Impact factor: 2.953
Authors: Myrthe P P van Herk-Sukel; Sumitra Shantakumar; Lucy I H Overbeek; Hester van Boven; Fernie J A Penning-van Beest; Ron M C Herings Journal: Sarcoma Date: 2012-05-28
Authors: Wesley Y Yu; Sheena T Hill; E Ricky Chan; John J Pink; Kevin Cooper; Sancy Leachman; Amanda W Lund; Rajan Kulkarni; Jeremy S Bordeaux Journal: J Invest Dermatol Date: 2021-01-06 Impact factor: 7.590
Authors: Christine Wasinger; Martin Künzl; Christoph Minichsdorfer; Christoph Höller; Maria Zellner; Martin Hohenegger Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739
Authors: Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria Journal: Mol Cancer Date: 2008-10-23 Impact factor: 27.401